Get the Stockscreener App
7.07
7.94%
+0.52
After Hours:
7.01
-0.06
-0.85%
Altimmune Inc stock is currently priced at $7.07, with a 24-hour trading volume of 4.11M.
It has seen a +7.94% increased in the last 24 hours and a -30.89% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.53 pivot point. If it approaches the $7.17 resistance level, significant changes may occur.
Previous Close:
$6.55
Open:
$6.64
24h Volume:
4.11M
Market Cap:
$501.23M
Revenue:
$426.00K
Net Income/Loss:
$-88.45M
P/E Ratio:
-4.3374
EPS:
-1.63
Net Cash Flow:
$-75.86M
1W Performance:
-0.14%
1M Performance:
-30.89%
6M Performance:
+188.57%
1Y Performance:
+43.70%
1D Range:
$6.55
$7.39
52W Range:
$2.09
$14.84
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
240-654-1450
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune to Participate at Two Upcoming Conferences
GlobeNewswire Inc.
Altimmune Statement on the Passing of Dr. Stephen Harrison
GlobeNewswire Inc.
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
The Motley Fool
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
The Motley Fool
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Altimmune Inc Stock (ALT) Financials Data
Altimmune Inc (ALT) Revenue 2024
ALT reported a revenue (TTM) of $426.00 thousand for the quarter ending December 31, 2023, a +726.47% rise year-over-year.
Altimmune Inc (ALT) Net Income 2024
ALT net income (TTM) was -$88.45 million for the quarter ending December 31, 2023, a -4.41% decrease year-over-year.
Altimmune Inc (ALT) Cash Flow 2024
ALT recorded a free cash flow (TTM) of -$75.86 million for the quarter ending December 31, 2023, a -20.96% decrease year-over-year.
Altimmune Inc (ALT) Earnings per Share 2024
ALT earnings per share (TTM) was -$1.67 for the quarter ending December 31, 2023, a +5.65% growth year-over-year.
About Altimmune Inc
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
3.18%
Cap:
|
Volume (24h):